Abstracts tagged "DMARDs"

Abstract Number: 1491 • 2015 ACR/ARHP Annual Meeting
Effects of Drug Induced Toxicity on Patient Reported Outcomes in Early Rheumatoid Arthritis Treated-to-Target Using Conventional Triple DMARD Therapy
Nasir Wabe¹, Michael Sorich², Mihir Wechalekar^2,3, Leslie Cleland³, Leah McWilliams³, Anita Lee^4,5, Llew Spargo⁴, Robert Metcalf³, Cindy Hall⁴, Susanna Proudman^4,5 and Michael D. Wiese⁶, ¹School of Pharmacy and Medical Sciences and Sansom Institute for Health Research, University of South Australia, Adelaide, Australia, ²Flinders University, Adelaide, Australia, ³Royal Adelaide Hospital, Adelaide, Australia, ⁴Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ⁵Discipline of Medicine, University of Adelaide, Adelaide, Australia, ⁶University of South Australia, Adelaide, Australia
Background/Purpose: While the introduction of the treat-to-target (T2T) strategy is associated with lower disease activity scores in rheumatoid arthritis (RA), the potential for increased toxicity…
Abstract Number: 2731 • 2015 ACR/ARHP Annual Meeting
Persistency of Tocilizumab As Monotherapy or Combination Therapy in Patients with Rheumatoid Arthritis–Real-World Analyses from the US Corrona Registry
Dimitrios A. Pappas^1,2, Ani John³, Carol J. Etzel^2,4, Chitra Karki², YouFu Li⁵, Joel M. Kremer⁶, Tmirah Haselkorn³ and Jeffrey D. Greenberg^2,7, ¹Columbia University, New York, NY, ²Corrona, LLC, Southborough, MA, ³Genentech, Inc, South San Francisco, CA, ⁴The University of Texas MD Anderson Cancer Center, Houston, TX, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶Albany Medical College and The Center for Rheumatology, Albany, NY, ⁷NYU School of Medicine, New York, NY
Background/Purpose: For patients with rheumatoid arthritis (RA), there are limited real-world data on factors that predict persistency on biologic therapy or whether use of biologics…
Abstract Number: 516 • 2015 ACR/ARHP Annual Meeting
Immunological and Ultrasound Characteristics of Patients with Rheumatoid Arthritis in Clinical Remission – Can We Use These to Predict Outcomes?
Hanna Gul¹, Maria Jesus Isorna Porto², Elizabeth M.A. Hensor³, Frederique Ponchel⁴, Richard J. Wakefield⁵ and Paul Emery⁶, ¹Rheumatology, Leeds Institute of Rheumatology and Musculoskeletal Medicine, Leeds, United Kingdom, ²Internal Medicine, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ³NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁴Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ⁵University of Leeds, Leeds, United Kingdom, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Remission is the key treatment goal in rheumatoid arthritis (RA). Although clinical remission is increasingly achieved, many patients progress both structurally and functionally. We…
Abstract Number: 1553 • 2015 ACR/ARHP Annual Meeting
Effect of Drug Therapy on Net Cholesterol Efflux Capacity of HDL-Enriched Serum in Rheumatoid Arthritis
Michelle J. Ormseth¹, S. Louis Bridges Jr.², Jeffrey R. Curtis³, Joseph F. Solus⁴, Patricia Yancey⁵, MacRae F. Linton⁶, Sean Davies⁶, L Jackson Roberts II⁷, Kasey C. Vickers⁶, Valentina Kon⁶, Sergio Fazio⁸, C Michael Stein⁶ and TETRAD Investigators, ¹Department of Medicine, Division of Rheumatology, Vanderbilt University, Nashville, TN, ²Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Pharmacology, Vanderbilt University, Nashville, TN, ⁵Medicine, Vanderbilt University, Nashville, TN, ⁶Vanderbilt University, Nashville, TN, ⁷Pharmacology, Vanderbilt University, Nashville, TN, ⁸Oregon Health and Science University, Portland, OR
Background/Purpose: Patients with rheumatoid arthritis (RA) have increased coronary heart disease risk. Some RA therapies may modify this risk, but underlying mechanisms are unclear. The…
Abstract Number: 2742 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Tofacitinib Monotherapy Versus Combination Therapy in a Latin American Subpopulation of Patients with Rheumatoid Arthritis: A Pooled Phase 3 Analysis
Cristiano Zerbini¹, Sebastiao Radominski², Mario H. Cardiel³, Oswaldo Castañeda⁴, Ferope Romero⁵, Gustavo Citera⁶, Oscar Neira⁷, Dario Ponce de Leon⁸, Elaine Hoffman⁹ and Ricardo Rojo¹⁰, ¹Centro Paulista de Investigação Clinica, São Paulo, Brazil, ²Universidade Federal do Paraná, Curitiba, Brazil, ³Centro de Investigacion Clinica de Morelia, Morelia, Mexico, ⁴Clínica Angloamericana, Lima, Peru, ⁵Hospital Arzobispo Loayza, Lima, Peru, ⁶Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁷Hospital del Salvador, Clínica Alemana, Santiago, Chile, ⁸Pfizer Inc, Lima, PA, Peru, ⁹Pfizer Inc, Groton, CT, ¹⁰Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. This post-hoc pooled analysis was designed to assess the efficacy and safety…
Abstract Number: 546 • 2015 ACR/ARHP Annual Meeting
Adipokines and Insulin-like Growth Factor 1 As Predictors of Clinical and Radiographic Outcomes in Early Rheumatoid Arthritis
Adrian Levitsky¹, Kerstin Brismar², Saedis Saevarsdottir³, Karen Hambardzumyan¹, Anna Andersson¹ and Ronald F. van Vollenhoven¹, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Department of Molecular Medicine and Surgery, Unit of Growth and Metabolism, The Karolinska Institute, Stockholm, Sweden, ³Department of Medicine, Rheumatology Unit, The Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Adipokines are cytokines/hormones primarily synthesized in white adipose tissue. In rheumatoid arthritis (RA), some adipokines have been associated with worse outcomes (1-3). The aim…
Abstract Number: 1634 • 2015 ACR/ARHP Annual Meeting
The Effects of Glucocorticoids on the Efficacy of Tofacitinib As Monotherapy and in Combination Therapy with Nonbiologic Dmards: An Analysis of Data from Six Phase 3 Studies
Roy Fleischmann¹, Christina Charles-Schoeman², Gerd Burmester³, Cristiano Zerbini⁴, Peter Nash⁵, Kenneth Kwok⁶, Koshika Soma⁷, Alan Mendelsohn⁸ and Eustratios Bananis⁸, ¹Metroplex Clinical Research Center, Dallas, TX, ²University of California, Los Angeles, CA, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Centro Paulista de Investigação Clinica, São Paulo, Brazil, ⁵Nambour Hospital, Sunshine Coast and Department of Medicine, University of Queensland, Queensland, Australia, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Patients with RA often receive concomitant treatment with glucocorticoids (GCs) to control…
Abstract Number: 2749 • 2015 ACR/ARHP Annual Meeting
A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Patients (pts) with Rheumatoid Arthritis (RA): Preliminary Results
Lei Zhou¹, Robert Sikorski¹, Seema Rogers¹, Stefan Costin², Mariusz Korkosz³, Maria Jaraczewska-Baumann⁴, Péterfai Éva⁵, Bernadette Rojkovich⁶, Janos Bartalos⁷, Emma Masteller¹, Hong Xiang¹, Brian Wong¹ and Julie Hambleton¹, ¹Five Prime Therapeutics, Inc., South San Francisco, CA, ²PRA Heath Sciences, Berlin, Germany, ³Malopolskie Centrum Medyczne, The University Hospital in Krakow, Krakow, Poland, ⁴MedPolonia Sp. z o.o, Poznan, Poland, ⁵Drug Research Center, Balatonfüred, Hungary, ⁶Hospitaller Brothers of St. John of God, Budapest, Hungary, ⁷PRA Hungary Ltd, Budapest, Hungary
Background/Purpose: FPA008 is a humanized IgG4 anti-CSF1R antibody that blocks the binding of CSF1 and IL34 ligands to CSF1R, resulting in inhibition of the activation…
Abstract Number: 557 • 2015 ACR/ARHP Annual Meeting
Early Intensification of Treatment Induces Superior Outcomes in Two Randomized Trials According to Predicted Vs. Observed Radiographic Progression in Rheumatoid Arthritis
Adrian Levitsky¹, Marius C. Wick², Timo Möttönen³, Marjatta Leirisalo-Repo⁴, Leena Laasonen⁵, Hannu Kautiainen^6,7, Markku Korpela⁸, Ronald F. van Vollenhoven¹ and Vappu Rantalaiho⁸, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Radiology, Karolinska University Hospital, Stockholm, Sweden, ³Internal Medicine, Division of Rheumatology, Turku University Central Hospital, Turku, Finland, ⁴Rheumatology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ⁵Helsinki Medical Imaging Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ⁶Unit of Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ⁷Unit of Primary Health Care, Kuopio University Hospital, Kuopio, Finland, ⁸Department of Internal Medicine, Center for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland
Background/Purpose: Predicted vs. Observed Radiographic Progression in early Rheumatoid Arthritis (POPeRA) is a method that has previously confirmed the relative radiographic efficacy of synthetic disease-modifying…
Abstract Number: 1639 • 2015 ACR/ARHP Annual Meeting
Clinical Outcomes for Rheumatoid Arthritis Patients Receiving Tofacitinib Monotherapy in the Open-Label Long-Term Extension over 6 Years
Roy Fleischmann¹, Yusuf Yazici², Jürgen Wollenhaupt³, Lisy Wang⁴, Anna Maniccia⁵, Kenneth Kwok⁴, Liza Takiya⁵ and Ronald van Vollenhoven⁶, ¹Rheumatology, Metroplex Clinical Research Center, Dallas, TX, ²New York University Hospital for Joint Diseases, New York, NY, ³Teaching Hospital of the University of Hamburg, Schoen-Klinik Hamburg-Eilbek, Hamburg, Germany, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶The Karolinska Institute, Stockholm, Sweden
Background/Purpose: Treatment options delivering sustained efficacy when given as monotherapy in RA are limited.1 Tofacitinib is an oral Janus kinase inhibitor for the treatment of…
Abstract Number: 2768 • 2015 ACR/ARHP Annual Meeting
Trend and Factors Associated with Switching Treatment after Initial Anti-TNF Therapy Among Patients with Rheumatoid Arthritis
Wenhui Wei¹, Emma Sullivan², Chieh-I Chen³, James Piercy² and Stuart Blackburn², ¹Sanofi-Aventis, Bridgewater, NJ, ²Adelphi Real World, Manchester, United Kingdom, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Among rheumatoid arthritis (RA) patients who progress beyond their first biologic disease-modifying antirheumatic drug (bDMARD), in-class cycling between different tumor necrosis factor inhibitors (TNFi)…
Abstract Number: 602 • 2015 ACR/ARHP Annual Meeting
Efficacy of Very Low Dose (100mg) Rituximab in Active Rheumatoid Arthritis Despite Combination DMARD-Single Center, Prospective, Observational Study
Padmanabha Shenoy¹ and Manish Bavaliya², ¹Dept. of rheumatology and clinical immunology, Amrita Institute of medical science and research institute, Kochi, India, ²Department of rheumatology and clinical immunology, Amrita institute of medical sciences and research institute, Kochi, India
Background/Purpose: Rituximab is an anti-CD20 antibody that represents a therapeutic alternative for the patients with rheumatoid arthritis. It has been proven that rituximab at a…
Abstract Number: 1640 • 2015 ACR/ARHP Annual Meeting
Effect of Methotrexate Dose on the Efficacy of Tofacitinib: Treatment Outcomes from a Phase 3 Clinical Trial of Patients with Rheumatoid Arthritis
Roy Fleischmann¹, Philip J. Mease², Sergio Schwartzman³, Lie-Ju Hwang⁴, Aditya Patel⁵, Koshika Soma⁴, Carol A. Connell⁶, Liza Takiya⁴ and Eustratios Bananis⁷, ¹Rheumatology, Metroplex Clinical Research Center, Dallas, TX, ²Rheumatology Research, Swedish Medical Center, Seattle, WA, ³Hospital for Special Surgery, New York, NY, ⁴Pfizer Inc, New York, NY, ⁵Inventiv Health Inc, South Plainfield, NJ, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). ORAL Scan was a 2-year, randomized, Phase 3, clinical trial…
Abstract Number: 2769 • 2015 ACR/ARHP Annual Meeting
Factors Associated with TNF Switching: a Retrospective Real-World Study of Patients with Rheumatoid Arthritis
Wenhui Wei¹, Keith Knapp², Li Wang³, Chieh-I Chen⁴, Gary Craig², Karen Ferguson² and Sergio Schwartzman⁵, ¹Sanofi-Aventis, Bridgewater, NJ, ²Discus Analytics, Inc., Spokane, WA, ³Director, Analytic Research, STATinMED Research, Plano, TX, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: Switching of disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patient treatment is common in real-world clinical practice. The context for why patients switch…
Abstract Number: 618 • 2015 ACR/ARHP Annual Meeting
The Multi-Biomarker Disease Activity Score in Methotrexate Incomplete Responders Predicts Clinical Responses to Non-Biological Versus Biological Therapy in Early RA
Karen Hambardzumyan¹, Rebecca J. Bolce², Saedis Saevarsdottir³, Kristina Forslind^4,5, Johan A Karlsson⁶ and Ronald F. van Vollenhoven¹, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Department of Medicine, Rheumatology Unit, The Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden, ⁴Department of Medicine, Helsingborgs Lasarett, Section of Rheumatology, Helsingborg, Sweden, ⁵Departments of Rheumatology, Helsingborgs Hospital and University of Lund, Helsingborg and Lund, Sweden, ⁶Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Background/Purpose: The Swedish Farmacotherapy (SWEFOT) trial and other trials in rheumatoid arthritis (RA) demonstrated that in MTX incomplete responder patients (MTX-IR) the addition of anti-TNF…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].